araag2/HINT huggingface dataset:
Clinical trial NCT00072280 (phase 2, status: terminated)
Conditions: sarcoma
ICD codes: C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: cyclophosphamide, etoposide, ifosfamide, vincristine sulfate
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Reason stopped: 
    due to poor accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed infantile, congenital, or pediatric fibrosarcoma

               -  Initial biopsy or surgery performed within the past 35 days

          -  No evidence of distant metastases

          -  Available tissue for central review

        PATIENT CHARACTERISTICS:

        Age

          -  Under 2 at diagnosis

        Performance status

          -  Zubrod Score (ECOG)

        Life expectancy

          -  At least 8 weeks

        Hematopoietic

          -  Absolute neutrophil count at least 1,000/mm^3

          -  Platelet count at least 100,000/mm^3*

          -  Hemoglobin at least 10.0 g/dL* NOTE: *Transfusions allowed

        Hepatic

          -  Total bilirubin no greater than 1.5 times upper limit of normal (ULN) (patients over 4
             weeks of age)

               -  Patients under 4 weeks of age with an indirect hyperbilirubinemia are eligible,
                  provided the following criteria are met:

                    -  At least 2 bilirubin values at separate timepoints show a decrease in
                       measurement

                    -  Direct bilirubin is no greater than 20% of the total bilirubin

          -  Direct bilirubin no greater than 1.5 times ULN

          -  Alanine Aminotransferase (ALT) less than 2.5 times ULN

        Renal

          -  Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min

        PRIOR/CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent sargramostim (GM-CSF)

        Chemotherapy

          -  No prior chemotherapy

          -  No other concurrent anticancer chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior or concurrent radiotherapy except emergent radiotherapy for impending
             tracheal compression

        Surgery

          -  See Disease Characteristics
Clinical trial NCT01031225 (phase 2, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: sta 9090
SMILES: CC(C)C1=CC(C2=NN=C(O)N2C2=CC=C3N(C)C=CC3=C2)=C(O)C=C1O
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologically confirmed diagnosis of Stage IIIB (with pleural effusion) or Stage IV
             NSCLC with measurable disease by RECIST and evidence of progression

          -  Availability of tissue for analysis

          -  ECOG Performance Status 0 or 1

          -  Adequate organ function as defined in the protocol.

          -  Must be at least 18 years old and able and willing to sign a written informed consent
             document

        Exclusion Criteria:

          -  Poor venous access requiring an indwelling catheter for study drug administration

          -  Women who are pregnant or lactating

          -  Ventricular ejection fraction < or = to 55% at baseline

          -  Any uncontrolled intercurrent illness
Clinical trial NCT00611247 (phase 2, status: completed)
Conditions: leukemia, myeloid
ICD codes: C92.Z1, C92.Z2, C92.91, C92.92, C92.Z0, C92.90, C92.11
Drugs: temozolomide
SMILES: CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patients must have histologically or cytologically confirmed Acute Myeloid Leukemia,
             as defined by the WHO classification.

          2. Patients must be considered unfit for conventional induction chemotherapy, unwilling
             to receive such treatment or have evidence of disease relapse or refractory disease.

          3. For patients who have received no prior conventional chemotherapy, one of the
             following must be present:

               -  Poor risk cytogenetics (complex abnormalities, deletions of chromosome 7 or 5,
                  11q23 abnormalities, inv[3])

               -  Secondary leukemia (prior hematologic disorder or therapy-related leukemia).

          4. Age > 60 years of age.

          5. Life expectancy of greater than 3 months.

          6. ECOG performance status greater than 2.

          7. Patients must have normal organ and marrow function as defined below:

          8. Adequate hepatic function: Total bilirubin 1.5mg/dL, AST(SGOT)/ALT(SGPT) 2.5 X
             institutional upper limit of normal.

          9. Adequate renal function: serum creatinine within normal institutional limits or
             Calculated creatinine clearance > 60 mL/min/1.73 m2 for patients with creatinine
             levels above institutional normal.

         10. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 4 weeks earlier.

          2. Patients may not be receiving any other investigational agents.

          3. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to temozolomide or DTIC

          4. History of gastrointestinal disease or significant bowel resection that could
             interfere with drug absorption.

          5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          6. Prior allogeneic stem cell transplantation.

          7. Inability to swallow tablets

          8. Prior radiation up to more than 25% of bone marrow.
Clinical trial NCT01173471 (phase 2, status: completed)
Conditions: raised intraocular pressure
ICD codes: Z96.1, T85.22XS, T85.21XS, T85.22XA, T85.22XD, T85.21XA, T85.21XD
Drugs: azd4017, placebo, azd4017, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must have a diagnosis of intra-ocular hypertension (raised IOP), or primary open-angle
             glaucoma (POAG), with IOP >20 mmHg and ≤36 mmHg in the study eye, and is currently
             prescribed a stable dose of a single anti-glaucoma medication that began at least 30
             days prior to the screening visit; OR

          -  Must have a diagnosis of intra-ocular hypertension (raised IOP), defined as an IOP ≥22
             mmHg and ≤36 mmHg in the study eye while not on anti-glaucoma medication

          -  Male patients must be willing to use barrier contraception with spermicide, ie,
             condoms, from the day of first dosing until 3 months after dosing with IP

          -  Placebo treatment for duration of the study must not be considered detrimental to the
             patient

        Exclusion Criteria:

          -  Have uncontrolled intra-ocular hypertension (>36 mmHg)

          -  Have experienced a significant visual field loss or showed evidence of progressive
             visual field loss within the last year (as defined by >1 dB/yr average loss or vision
             threatening new defect)

          -  Have had severe eye trauma at any time
Clinical trial NCT00191724 (phase 2, status: completed)
Conditions: submassive pulmonary embolism
ICD codes: A21.2, A22.1, A42.0, A43.0, B37.1, B41.0, B42.0
Drugs: drotrecogin alfa (activated), enoxaparin, placebo, drotrecogin alfa (activated), drotrecogin alfa (activated), drotrecogin alfa (activated)
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Patients with symptoms of acute pulmonary embolism (PE), without an indication for
        fibrinolytic therapy but with echocardiographic evidence of right ventricular dysfunction
        (submassive PE) within 48 hours of onset of symptoms

        Inclusion Criteria:

          -  Clinical symptoms of Pulmonary embolism for less than 48 hours

        Exclusion Criteria:

          -  Patients with symptoms of Pulmonary embolism for more than 48 hours
Clinical trial NCT00431782 (phase 2, status: completed)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: ati-5923
SMILES: CC(OC(=O)C1=CC=C(CC2=C(O)C3=CC=CC=C3OC2=O)C=C1)(C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Documented atrial fibrillation

          -  Candidate for anticoagulation or currently receiving warfarin at screening

          -  Males or females greater than 18 years of age

          -  Males or females with a CHADS2 score of 0 to 2

        Exclusion Criteria:

          -  Contraindications to anticoagulation e.g., active bleeding

          -  Taking other anticoagulant or antiplatelet agents other than low-dose aspirin

          -  History of myocardial infarction, acute coronary syndrome, or coronary
             revascularization procedure within the past 3 months prior to Day 1

          -  History of laboratory values suggestive of anemia (i.e., Hb <10 gm/dL)

          -  Women of childbearing potential
Clinical trial NCT00268242 (phase 2, status: terminated)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: gemcitabine hydrochloride, mitoxantrone hydrochloride
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O
Reason stopped: 
    if </= 5 of the initial 18 patients had a cr, the study would be stopped. only 5 patients (21%)
    of 24 enrolled patients had a cr so the study was terminated.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Bone marrow examination or peripheral blood analysis confirming active acute myeloid
             leukemia by WHO criteria

               -  No M3 acute myeloid leukemia

          -  Not a candidate for allogenic bone marrow transplantation

          -  Patient must be in first relapse after having received induction chemotherapy

               -  Received 1 or 2 courses with remission lasting at least 1 month

          -  Patients with chloromas or leukemia cutis are eligible

          -  No evidence of leptomeningeal involvement

        PATIENT CHARACTERISTICS:

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

          -  Liver enzymes (total bilirubin, aspartate aminotransferase (AST) and ALT) ≤ 2.5 times
             the upper limits of normal

               -  Liver enzymes ≥ 2.5 are acceptable if physician documents that it is secondary to
                  the disease

          -  Serum creatinine ≤ 3 mg/dL

          -  No poorly controlled medical conditions that would seriously complicate compliance
             with this study

          -  No other active primary malignancy other than carcinoma in situ of the cervix or basal
             cell carcinoma of the skin

          -  No New York Heart Association grade III or IV cardiac problems, defined as congestive
             heart failure or myocardial infarction within 6 months prior to start of study

          -  Pregnant or nursing women are ineligible

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after study
             participation

          -  No documented history of human immunodeficiency virus (HIV) infection

          -  No history of chronic liver disease

          -  Ejection fraction ≥ 45%

          -  No significant history of non-compliance to medical regimens or inability to give
             reliable informed consent

        PRIOR CONCURRENT THERAPY:

          -  Previous treatment related toxicities should be resolved to grade 1 or better

          -  No other investigational agents within 14 days prior to the start of study

          -  No chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to
             start of study

          -  No major surgery within 2 weeks prior to start of study

          -  At least two weeks must have elapsed since the conclusion of radiation therapy and the
             start of gemcitabine hydrochloride, provided the acute effects of radiation treatment
             have been resolved
Clinical trial NCT00568061 (phase 2, status: terminated)
Conditions: acute myocardial infarction, st elevation mi, stemi
ICD codes: I21.9, I23.8, I23.0, I24.0, I23.1, I23.2, I23.4
Drugs: nitric oxide, placebo
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    slow enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Acute myocardial infarction and electrocardiographic evidence of ST elevation

          -  No clinical evidence of congestive heart failure

          -  All patients must undergo successful percutaneous coronary intervention for
             thrombolysis in myocardial infarction (TIMI) 0 or 1 coronary flow with resulting TIMI
             2 or 3 flow

          -  Greater than 18 years of age

          -  Signed Institutional Review Board (IRB) approved informed consent

        Exclusion Criteria:

          -  Prior myocardial infarction

          -  Requirement for urgent cardiac surgery

          -  Previous coronary artery bypass graft (CABG) or primary coronary intervention (PCI)

          -  Left bundle branch block

          -  Heart block that is expected to require a temporary pacemaker for greater than 72
             hours

          -  Prior use of thrombolytic therapy for the current event

          -  Unable to tolerate magnetic resonance imaging or unable to tolerate gadolinium
             contrast media, including patients with a calculated creatinine clearance less than 60
             ml/min/1.73m² Body Surface Area (BSA)

          -  Active or recent hemorrhage requiring an invasive procedure for evaluation or
             transfusion within 6 weeks prior to presentation, or hemorrhagic stroke within the 6
             weeks prior

          -  Neutropenia (WBC <2000 (mm)³), Anemia (HCT <30%, Thrombocytopenia (Thrombocytes
             <50,000 (mm)³). It is not necessary to confirm blood counts prior to start of study
             drug in the absence of clinical suspicion.

          -  Known or suspected aortic dissection.

          -  Prior history of pulmonary disease requiring chronic oxygen therapy.

          -  Pregnancy, lactating, and women of childbearing potential.

          -  Medical problem likely to preclude completion of the study.

          -  Use of investigational drugs or device within the 30 days prior to enrollment
Clinical trial NCT00619866 (phase 2, status: completed)
Conditions: endometriosis, pain
ICD codes: N80.8, N80.9, N80.0, N80.1, N80.5, N80.2, N80.3
Drugs: elagolix, placebo
SMILES: COC1=C(F)C(=CC=C1)C1=C(C)N(CC2=C(C=CC=C2F)C(F)(F)F)C(=O)N(C[C@H](NCCCC(O)=O)C2=CC=CC=C2)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Be female, aged 18 to 49 years, inclusive

          -  Have moderate to severe pelvic pain due to endometriosis

          -  Have been surgically (laparoscopy) diagnosed with endometriosis within the last 8
             years and have recurrent or persistent endometriosis symptoms

          -  Have regular menstrual cycle

          -  Have a body mass index (BMI) of 18 to 36 kg/m², inclusive

          -  Agree to use two forms of non-hormonal contraception during the study

        Exclusion Criteria:

          -  Are currently receiving gonadotropin-releasing hormone (GnRH) agonist or GnRH
             antagonist or have received any of these agents within 6 months of the start of
             screening

          -  Are currently receiving subcutaneous medroxyprogesterone acetate (DMPA-SC) or
             intramuscular medroxyprogesterone acetate (DMPA-IM) or have received any of these
             agents within 3 months of the start of screening

          -  Are currently using hormonal contraception or other forms of hormonal therapy or
             received such treatment within the last month

          -  Have had surgery for endometriosis within the last month

          -  Have had a hysterectomy or bilateral oophorectomy

          -  Are using systemic steroids on a chronic or regular basis within 3 months

          -  Have uterine fibroids ≥ 3 cm in diameter

          -  Have pelvic pain that is not caused by endometriosis

          -  Have unstable medical condition or chronic disease

          -  Have been pregnant within the last six months

          -  Currently breast feeding
Clinical trial NCT00524810 (phase 2, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: pegylated liposomal doxorubicin, docetaxel
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  first metastatic chemo line

          -  presence of measurable or bone lesion

          -  at least one lesion outside the radiated areas

          -  can have previously received hormonotherapy, chemotherapy in adjuvant phase,
             radiotherapy if older than 4 weeks

        Exclusion Criteria:

          -  only local tumoral progression

          -  symptomatic cerebral metastasis

          -  neuropathy > NCI-CTC 2

          -  previous cancer within 10 years _ previous cancer within 10 years
Clinical trial NCT00461682 (phase 2, status: terminated)
Conditions: irritable colon
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: sb-705498
SMILES: FC(F)(F)C1=CC=C(N=C1)N1CC[C@H](C1)NC(=O)NC1=CC=CC=C1Br
Eligibility criteria:

        Inclusion Criteria:

          -  Female/male aged 18-65.

          -  Women of child bearing potential must use an effective method of contraception

          -  Faecal urgency as defined by Chan

          -  ECG, which has no abnormalities

          -  Normal Clinical labs

          -  Informed consent and understand protocol requirements

          -  IBS subjects: Has irritable bowel syndrome (IBS) as defined by Rome II criteria

          -  Rectal hyperalgesia

        Exclusion Criteria:

          -  Any clinical or biological abnormality found at screen (other than those related to
             the disease under investigation)

          -  History of alcohol, substance or drug abuse

          -  Uncontrolled hypertension

          -  A history or presence of cardiovascular risk factors

          -  Participation in a trial within 3 months before the start of the study

          -  History of allergy

          -  Unable to withdraw from analgesic medications for their rectal hyperalgesia
             (opioid-dependent patients can be included if they are willing to withdraw from their
             opiate medication
Clinical trial NCT00535418 (phase 2/phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: letrozole
SMILES: N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N
Eligibility criteria:

        Inclusion criteria:

          1. Female Breast Cancer patients with primary invasive breast cancer, histologically
             confirmed by core needle biopsy, whose tumors are estrogen (ER) and / or progesterone
             (PgR) positive (Clinical Stage *T2, T3, T4a,b,c, N0, M0)

          2. Patients after menopause

          3. Tumor measurable by clinical examination, mammography and ultrasound

          4. Adequate bone marrow, renal and hepatic function

          5. A life expectancy of at least 6 months.

        Exclusion criteria:

          1. Prior treatment with aromatase inhibitors or antiestrogens.

          2. Uncontrolled endocrine disorders such as diabetes mellitus, confirmed hypo- or
             hyperthyroidism, Cushing´s Syndrome, Addison´s disease (treated or untreated),
             Patients with unstable angina, uncontrolled cardiac disease (e.g. Class II or IV New
             York Heart Association's Functional Classification).

          3. Patients with tumors in both breasts, evidence of inflammatory breast cancer or
             distant metastasis

          4. Patients who are eligible for breast conserving surgery.

          5. Concomitant anti-cancer treatments such as chemotherapy, immunotherapy/biological
             response modifiers (BRM's), endocrine therapy (including steroids), bisphosphonate
             therapy and radiotherapy. Patients who have received HRT will NOT be excluded,
             provided that HRT is discontinued at least 2 weeks prior to entry into the study.

        Other protocol defined inclusion/exclusion criteria may apply
Clinical trial NCT00377325 (phase 2, status: withdrawn)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: cyclosporine
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Reason stopped: 
    study terminated by the dsmb due to low recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Good health

          -  Exception that has been resistant to psoralen and ultraviolet A radiation (PUVA),
             methotrexate, and retinoids

          -  Moderate to severe, stable plaque psoriasis

          -  Normal organ and marrow function

          -  HIV uninfected

        Exclusion Criteria:

          -  Topical therapy within 4 weeks of study entry

          -  Use of systemic, intralesional, or phototherapy within 1 year of study entry

          -  Use of cyclosporine in the past or use of other immunosuppressive medication within 6
             months of study entry

          -  Inability to be followed or monitored regularly on a weekly basis

          -  Poorly controlled hypertension

          -  Severe infection, internal malignancy, immunodeficiency, gout, or liver disease

          -  Received more than 1,000 treatments of ultraviolet A (UVA)

          -  History of allergic reaction attributed to compounds of similar chemical or biological
             composition to cyclosporine

          -  Uncontrolled active infection, symptomatic congestive heart failure, unstable angina
             pectoris, or cardiac arrhythmia that would limit study participation

          -  Women of childbearing potential and men unwilling to use adequate contraception
             (hormonal or barrier method of birth control or abstinence) prior to study entry and
             for the duration of the study

          -  Pregnant